HOLX - Hologic, Inc.
48.52 0.00 (0.00%)
After hours: 5:07PM EDT
| Previous Close | 49.07 |
| Open | 49.01 |
| Bid | 48.43 x 1400 |
| Ask | 49.01 x 800 |
| Day's Range | 48.33 - 49.11 |
| 52 Week Range | 37.47 - 49.78 |
| Volume | 1,338,037 |
| Avg. Volume | 1,424,253 |
| Market Cap | 13.006B |
| Beta (3Y Monthly) | 0.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.04 |
| Earnings Date | Jul 29, 2019 - Aug 2, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 48.33 |
- Zacks•3 days ago
Veracyte (VCYT) Hits Fresh High: Is There Still Room to Run?
Veracyte (VCYT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- Zacks•3 days ago
Here's Why You Should Add Hologic (HOLX) to Your Portfolio
Hologic (HOLX) is generating consistent positive results, courtesy of growth initiatives.
- Zacks•3 days ago
Hologic (HOLX) Inks Deal to Acquire SuperSonic Imagine
The acquisition of SuperSonic Imagine is in sync with Hologic's (HOLX) strategy to provide wide-ranging screening, interventional and surgical solutions.
- Benzinga•3 days ago
The Daily Biotech Pulse: ContraVir's Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 20) Abbott Laboratories (NYSE: ABT ) ANI Pharmaceuticals ...
- Business Wire•4 days ago
Hologic Enters into Exclusive Negotiations to Acquire SuperSonic Imagine, French Ultrasound Innovator
Hologic, Inc. (HOLX), a global leader in women’s health, announced today that it has made a binding offer to acquire (directly or through an affiliate) SuperSonic Imagine (Euronext: SSI, FR0010526814), a France-based innovator in cart-based ultrasound products, and that it has entered into an exclusive negotiation agreement with the company and its main shareholders toward that end. “Like our previous acquisitions of Faxitron and Focal, acquiring SuperSonic Imagine will strengthen our strategy to provide comprehensive screening, interventional and surgical solutions across the continuum of breast health care,” said Pete Valenti, Hologic’s Division President, Breast and Skeletal Health Solutions. Under the terms of the binding offer, Hologic has agreed to acquire SuperSonic Imagine’s outstanding shares at a price of €1.50 per share.
- Insider Monkey•11 days ago
Is Hologic, Inc. (HOLX) A Good Stock To Buy?
At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Tiger Global because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps […]
- Zacks•11 days ago
HOLX or EW: Which Is the Better Value Stock Right Now?
HOLX vs. EW: Which Stock Is the Better Value Option?
- Business Wire•11 days ago
Hologic Receives Manufacturing Leadership Awards for Operational Excellence and Sustainability
Company’s Costa Rica and Danbury, CT manufacturing facilities recognized for energy savings and operational efficiency initiatives
- Markit•14 days ago
See what the IHS Markit Score report has to say about Hologic Inc.
Hologic Inc NASDAQ/NGS:HOLXView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for HOLX with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting HOLX. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding HOLX totaled $11.53 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Simply Wall St.•17 days ago
A Look At The Fair Value Of Hologic, Inc. (NASDAQ:HOLX)
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Hologic, Inc...
- Zacks•24 days ago
Hologic (HOLX) Down 5.2% Since Last Earnings Report: Can It Rebound?
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Business Wire•25 days ago
Hologic Partners with DEXA+ to Distribute Body Composition Measurement System
Hologic, Inc. (HOLX) announced today that it has signed an agreement with DEXA+ to distribute Hologic’s Horizon® DXA system for body composition measurement. With over 20 years of experience, DEXA+ works with healthcare practices nationwide to implement and optimize DXA technology to grow integrative medicine, health and wellness programs. The partnership allows Hologic to expand its expertise in body composition assessment and the reach of its market-leading DXA system.
- Business Wire•26 days ago
FDA Clearance of Aptima BV and Aptima CV/TV Molecular Assays Ushers in New Era of Comprehensive and Objective Diagnostic Testing for Vaginitis
--Improved accuracy in identifying bacterial vaginosis , vulvovaginal candidiasis and trichomoniasis will enable more target
- Business Wire•27 days ago
Hologic to Webcast Presentations at Upcoming Investor Conferences
Hologic, Inc. announced today that the Company will present at these upcoming investor conferences:
- Zacks•last month
Hologic Breast Health Arm Aids Strongly, Rising Costs Ail
Within Breast Health, Hologic (HOLX) unveils a string of products including 3Dimensions and 3D Performance gantries, Clarity HD, SmartCurve, Affirm prone biopsy system and Brevera biopsy system.
- Zacks•last month
HOLX vs. EW: Which Stock Is the Better Value Option?
HOLX vs. EW: Which Stock Is the Better Value Option?
GuruFocus.com•2 months agoKahn Brothers Trims New York Times, Hologic Positions
Founded in 1978, Kahn Brothers (Trades, Portfolio) & Co. Inc. currently manages more than $800 million in assets. Warning! GuruFocus has detected 3 Warning Sign with BOM:532772. The trade had an impact of -2.24% on the portfolio.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of HOLX earnings conference call or presentation 1-May-19 8:30pm GMT
Q2 2019 Hologic Inc Earnings Call
- CNBC•2 months ago
Cramer Remix: Why buybacks have not benefited Bed Bath & Beyond
Jim Cramer explains how the retailer has hurt itself by spending fortunes buying back stock.
- Zacks•2 months ago
Hologic's (HOLX) Q2 Earnings Beat Estimates, Margins Fall
Hologic (HOLX) registers solid Q1year-over-year revenue growth in core businesses like Breast Health and Molecular Diagnostics.
- Business Wire•2 months ago
Hologic Showcases Growing Portfolio of Women’s Health Products at 2019 American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting
Company to host timely educational panel on breast density featuring leading clinicians
Motley Fool•2 months agoHologic Inc (HOLX) Q2 2019 Earnings Call Transcript
HOLX earnings call for the period ending March 30, 2019.
- CNBC•2 months ago
Hologic CEO: Preventing false positives with 3D mammography technology
Hologic CEO Stephen MacMillan explains to Jim Cramer how the company is using technology to address challenges in women's health.
